BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

...data sets so far from Amgen Inc., Bayer AG, Eli Lilly & Co. and the Alliance for Clinical Trials in Oncology...
...study by switching away from standard-of-care than patients in clinical trials. Companies and Institutions Mentioned Alliance for Clinical Trials in Oncology...
BioCentury | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

...GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use...
...to disclose additional details. GNS Healthcare Inc., Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Alliance for Clinical Trials in Oncology...
...Boston, Mass. Business: Cancer Shannon Lehnbeuter Vectibix, panitumumab (ABX-EGF) Amgen Inc. GNS Healthcare Inc. Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Alliance for Clinical Trials in Oncology...
BioCentury | Oct 20, 2017
Clinical News

Exelixis, Ipsen report additional Phase II data for cabozantinib in untreated RCC

...investigator assessment vs. Sutent (8.3 vs. 5.4 months, p=0.0042). The trial was conducted by the Alliance for Clinical Trials in Oncology...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | May 30, 2016
Clinical News

Cabometyx cabozantinib: Phase II data

...the primary endpoint of improving PFS vs. Sutent sunitinib. The trial was conducted by the Alliance for Clinical Trials in Oncology...
BioCentury | Dec 14, 2015
Clinical News

Midostaurin: Phase III data

...vs. 3 months, HR=0.79, 95% CI: 0.67, 0.95, p=0.0025). The trial was sponsored by the Alliance for Clinical Trials in Oncology...
BioCentury | May 12, 2015
Company News

Project Data Sphere tops first-year target

...of Merck KGaA (Xetra:MRK), Eli Lilly and Co. (NYSE:LLY), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), and the Alliance for Clinical Trials in Oncology...
BioCentury | Sep 1, 2014
Clinical News

Tarceva erlotinib: Phase III started

...a dual inhibitor of c-Met receptor tyrosine kinase and ALK and their oncogenic variants. The Alliance for Clinical Trials in Oncology...
BioCentury | Sep 1, 2014
Clinical News

Xalkori crizotinib: Phase III started

...is majority owned by Roche, has rights to Tarceva in Japan. Pfizer markets Xalkori. The Alliance for Clinical Trials in Oncology...
BioCentury | Aug 19, 2014
Clinical News

NCI launches second precision medicine master protocol

...Tarceva in the U.S., while Roche markets it elsewhere. Pfizer Inc. (NYSE:PFE) markets Xalkori. The Alliance for Clinical Trials in Oncology...
Items per page:
1 - 10 of 14
BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

...data sets so far from Amgen Inc., Bayer AG, Eli Lilly & Co. and the Alliance for Clinical Trials in Oncology...
...study by switching away from standard-of-care than patients in clinical trials. Companies and Institutions Mentioned Alliance for Clinical Trials in Oncology...
BioCentury | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

...GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use...
...to disclose additional details. GNS Healthcare Inc., Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Alliance for Clinical Trials in Oncology...
...Boston, Mass. Business: Cancer Shannon Lehnbeuter Vectibix, panitumumab (ABX-EGF) Amgen Inc. GNS Healthcare Inc. Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Alliance for Clinical Trials in Oncology...
BioCentury | Oct 20, 2017
Clinical News

Exelixis, Ipsen report additional Phase II data for cabozantinib in untreated RCC

...investigator assessment vs. Sutent (8.3 vs. 5.4 months, p=0.0042). The trial was conducted by the Alliance for Clinical Trials in Oncology...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | May 30, 2016
Clinical News

Cabometyx cabozantinib: Phase II data

...the primary endpoint of improving PFS vs. Sutent sunitinib. The trial was conducted by the Alliance for Clinical Trials in Oncology...
BioCentury | Dec 14, 2015
Clinical News

Midostaurin: Phase III data

...vs. 3 months, HR=0.79, 95% CI: 0.67, 0.95, p=0.0025). The trial was sponsored by the Alliance for Clinical Trials in Oncology...
BioCentury | May 12, 2015
Company News

Project Data Sphere tops first-year target

...of Merck KGaA (Xetra:MRK), Eli Lilly and Co. (NYSE:LLY), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), and the Alliance for Clinical Trials in Oncology...
BioCentury | Sep 1, 2014
Clinical News

Tarceva erlotinib: Phase III started

...a dual inhibitor of c-Met receptor tyrosine kinase and ALK and their oncogenic variants. The Alliance for Clinical Trials in Oncology...
BioCentury | Sep 1, 2014
Clinical News

Xalkori crizotinib: Phase III started

...is majority owned by Roche, has rights to Tarceva in Japan. Pfizer markets Xalkori. The Alliance for Clinical Trials in Oncology...
BioCentury | Aug 19, 2014
Clinical News

NCI launches second precision medicine master protocol

...Tarceva in the U.S., while Roche markets it elsewhere. Pfizer Inc. (NYSE:PFE) markets Xalkori. The Alliance for Clinical Trials in Oncology...
Items per page:
1 - 10 of 14